Josep Carreras Leukaemia Research Institute
🇪🇸Spain
- Country
- 🇪🇸Spain
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 101
- Market Cap
- -
- Website
- https://www.intercept-mds.eu
Clinical Trials
2
Active:0
Completed:1
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples
Recruiting
- Conditions
- Myelodysplastic Syndromes
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Josep Carreras Leukaemia Research Institute
- Target Recruit Count
- 200
- Registration Number
- NCT04251078
- Locations
- 🇪🇸
Josep Carreras Leukaemia Research Institute, Badalona, Barcelona, Spain
IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up
Completed
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Josep Carreras Leukaemia Research Institute
- Target Recruit Count
- 354
- Registration Number
- NCT04242849
News
Novel CAR-T Cell Therapy Shows 100% Response Rate in Refractory CD30+ Lymphoma Patients
A groundbreaking CAR-T cell therapy targeting CD30 protein (HSP-CAR30) has achieved a 100% overall response rate in patients with refractory CD30+ lymphoma, with 50% achieving complete remission.
Novel TIM-3 Decoy Enhances CAR-T Cell Therapy Efficacy in B-Cell Acute Lymphoblastic Leukemia
International researchers have developed a promising TIM-3 decoy mechanism that prevents B-ALL tumor cells from deactivating CAR-T cells, potentially addressing the high relapse rate in current treatments.